Thyroid-Associated Orbitopathy: Who and How to Treat

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 2, 2009, Pages 373-388

  Dickinson, Jane ^a   Perros, Petros ^a  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Graves' disease; Ophthalmopathy; Orbitopathy; Thyroid

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

DECOMPRESSION SURGERY; DISEASE COURSE; DISEASE SEVERITY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYE SURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

GRAVES OPHTHALMOPATHY; HUMANS; PATIENT CARE TEAM; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX;

EID: 62749130574     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.01.004     Document Type: Review

References (79)

1. Bartley G.B., and Gorman C.A. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol 119 6 (1995) 792-795
2. Dickinson A.J., and Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 55 3 (2001) 283-303
3. Soroudi A.E., Goldberg R.A., and McCann J.D. Prevalence of asymmetric exophthalmos in Graves orbitopathy. Ophthal Plast Reconstr Surg 20 3 (2004) 224-225
4. Von Arx G. Atypical manifestations. In: Wiersinga W.M., and Kahaly G.J. (Eds). Graves' orbitopathy: a multidisciplinary approach (2007), S Karger AG, Basel (Switzerland) 212-220
5. Rundle F.F., and Wilson C.W. Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clin Sci 5 (1944) 177-194
6. Perros P., and Kendall-Taylor P. Natural history of thyroid eye disease. Thyroid 8 5 (1998) 423-425
7. Mourits M.P., Koornneef L., Wiersinga W.M., et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73 8 (1989) 639-644
8. Prummel M.F., Wiersinga W.M., and Mourits M.P. Assessment of disease activity of Graves' ophthalmopathy. In: Prummel M.F. (Ed). Recent developments in Graves' ophthalmopathy (2000), Kluwer Academic Publishers, London 59-80
9. Kendler D.L., Lippa J., and Rootman J. The initial clinical characteristics of Graves' orbitopathy vary with age and sex. Arch Ophthalmol 111 2 (1993) 197-201
10. Bartley G.B., Fatourechi V., Kadrmas E.F., et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121 3 (1996) 284-290
11. Khan J.A., Doane J.F., and Whitacre M.M. Does decompression diminish the discomfort of severe dysthyroid orbitopathy?. Ophthal Plast Reconstr Surg 11 2 (1995) 109-112
12. Wiersinga W.M., Perros P., Kahaly G.J., et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155 3 (2006) 387-389
13. McKeag D., Lane C.M., Lazarus J.H., et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol 91 4 (2007) 455-458
14. Gerding M.N., Prummel M.F., Kalmann R., et al. The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy. J Endocrinol Invest 21 7 (1998) 459-462
15. Available at:. www.eugogo.org
16. Mourits M.P., Prummel M.F., Wiersinga W.M., et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47 1 (1997) 9-14
17. Terwee C.B., Prummel M.F., Gerding M.N., et al. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol 62 (2005) 145-155
18. Bartalena L., Baldeschi L., Dickinson A., et al., European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158 3 (2008) 273-285
19. Bahn R.S., and Gorman C.A. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 16 2 (1987) 391-407
20. Dickinson A.J. Clinical manifestations. In: Wiersinga W.M., and Kahaly G.J. (Eds). Graves' orbitopathy: a multidisciplinary approach (2007), S Karger AG, Basel (Switzerland) 1-26
21. Coulter I., Frewin S., Krassas G.E., et al. Psychological implications of Graves' orbitopathy. Eur J Endocrinol 157 2 (2007) 127-131
22. Thornton J., Kelly S.P., Harrison R.A., et al. Cigarette smoking and thyroid eye disease: a systematic review. Eye 21 9 (2007) 1135-1145
23. Prummel M.F., Wiersinga W.M., Mourits M.P., et al. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 121 Suppl 2 (1989) 185-189
24. Prummel M.F., Wiersinga W.M., Mourits M.P., et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150 5 (1990) 1098-1101
25. Tallstedt L., Lundell G., Blomgren H., et al. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine therapy?. Eur J Endocrinol 130 5 (1990) 494-497
26. Bartalena L., Marcocci C., Bogazzi F., et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338 2 (1998) 73-78
27. Perros P., Kendall-Taylor P., Neoh C., et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 90 9 (2005) 5321-5323
28. Uddin J.M., and Davies P.D. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 109 6 (2002) 1183-1187
29. Kikkawa D.O., Cruz Jr. R.C., Christian W.K., et al. Botulinum A toxin injection for restrictive myopathy of thyroid-related orbitopathy: effects on intraocular pressure. Am J Ophthalmol 135 4 (2003) 427-431
30. Hart R.H., and Perros P. Glucocorticoids in the medical management of Graves' ophthalmopathy. Minerva Endocrinol 28 3 (2003) 223-231
31. Marcocci C., Bartalena L., Tanda M.L., et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86 8 (2001) 3562-3567
32. Kahaly G.J., Pitz S., Hommel G., et al. Randomized, single-blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90 90 (2005) 5234-5240
33. Hart R.H., Kendall-Taylor P., Crombie A., et al. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther 21 4 (2005) 328-336
34. Marinò M., Morabito E., Brunetto M.R., et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 14 5 (2004) 403-406
35. Le Moli R., Baldeschi L., Saeed P., et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 17 4 (2007) 357-362
36. Kahaly G., Schrezenmeir J., Krause U., et al. Ciclosporin and prednisone vs. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16 5 (1986) 415-422
37. Prummel M.F., Mourits M.P., Berghout A., et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 321 20 (1989) 1353-1359
38. Wiersinga W.M. Management of Graves' ophthalmopathy. Nat Clin Pract Endocrinol Metab 3 5 (2007) 396-404
39. Mourits M.P., van Kempen-Harteveld M.L., Garcia M.B., et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 355 9214 (2000) 1505-1509
40. Prummel M.F., Terwee C.B., Gerding M.N., et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 89 1 (2004) 15-20
41. Gorman C.A., Garrity J.A., Fatourechi V., et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' orbitopathy. Ophthalmology 108 9 (2001) 1523-1534
42. Bartalena L., Marcocci C., Chiovato L., et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 56 6 (1983) 1139-1144
43. Marcocci C., Bartalena L., Bogazzi F., et al. Orbital radiotherapy combined with high-dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study. J Endocrinol Invest 14 10 (1991) 853-860
44. Garrity J.A., and Bahn R.S. Pathogenesis of Graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 142 1 (2006) 147-153
45. Paridaens D., van den Bosch W.A., van der Loos T.L., et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 19 12 (2005) 1286-1289
46. Salvi M., Vannucchi G., Campi I., et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156 1 (2007) 33-40
47. Wakelkamp I.M., Baldeschi L., Saeed P., et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 63 3 (2005) 323-328
48. Farid M., Roch-Levecq A.C., Levi L., et al. Psychological disturbance in Graves ophthalmopathy. Arch Ophthalmol 123 4 (2005) 491-496
49. Tehrani M., Krummenauer F., Mann W.J., et al. Disease-specific assessment of quality of life after decompression surgery for Graves' ophthalmopathy. Eur J Ophthalmol 14 3 (2004) 193-199
50. Schotthoefer E.O., and Wallace D.K. Strabismus associated with thyroid eye disease. Curr Opin Ophthalmol 18 5 (2007) 361-365
51. Baldeschi L., Wakelkamp I.M., Lindeboom R., et al. Early versus late orbital decompression in Graves' orbitopathy: a retrospective study in 125 patients. Ophthalmology 113 5 (2006) 874-878
52. Ben Simon G.J., Mansury A.M., Schwarcz R.M., et al. Simultaneous orbital decompression and correction of upper eyelid retraction versus staged procedures in thyroid-related orbitopathy. Ophthalmology 112 5 (2005) 923-932
53. Bahn R.S. Is orbital decompression a safe and effective treatment for Graves' orbitopathy?. Nat Clin Pract Endocrinol Metab 3 12 (2007) 796-797
54. Baldeschi L., MacAndie K., Hintschich C., et al. The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia. Am J Ophthalmol 140 4 (2005) 642-647
55. McCann J.D., Goldberg R.A., Anderson R.L., et al. Medial wall decompression for optic neuropathy but lateral wall decompression with fat removal for non vision-threatening indications. Am J Ophthalmol 141 5 (2006) 916-917
56. Baldeschi L. Orbital decompression. In: Wiersinga W.M., and Kahaly G.J. (Eds). Graves' orbitopathy: a multidisciplinary approach (2007), S Karger AG, Basel (Switzerland) 163-175
57. Kikkawa D.O., Pornpanich K., Cruz Jr. R.C., et al. Graded orbital decompression based on severity of proptosis. Ophthalmology 109 7 (2002) 1219-1224
58. Paridaens D., Lie A., Grootendorst R.J., et al. Efficacy and side effects of 'swinging eyelid' orbital decompression in Graves' orbitopathy: a proposal for standardized evaluation of diplopia. Eye 20 2 (2006) 154-162
59. Abramoff M.D., Kalman R., de Graaf M.E.L., et al. Rectus extraocular muscle paths and decompression surgery for Graves' orbitopathy: mechanism of motility disturbances. Invest Ophthalmol Vis Sci 43 2 (2002) 300-307
60. Goldberg R.A., Perry J.D., Hortaleza V., et al. Strabismus after balanced medial plus lateral wall versus lateral wall only orbital decompression for dysthyroid orbitopathy. Ophthal Plast Reconstr Surg 16 4 (2000) 271-277
61. Kacker A., Kazim M., Murphy M., et al. "Balanced" orbital decompression for severe Graves' orbitopathy: technique with treatment algorithm. Otolaryngol Head Neck Surg 128 (2003) 228-235
62. Richter D.F., Stoff A., and Olivari N. Transpalpebral decompression of endocrine ophthalmopathy by intraorbital fat removal (Olivari technique): experience and progression after more than 3000 operations over 20 years. Plast Reconstr Surg 120 1 (2007) 109-123
63. Pitz S., Esch A., Müller-Forell W.S., et al. Is there a relationship between the degree of preoperative motility impairment or the muscle thickness and the outcome of strabismus surgery in patients with Graves' orbitopathy after decompression surgery?. Orbit 24 3 (2005) 173-176
64. Mourits M.P., Koornneef L., van Mourik-Noordenbos A.M., et al. Extraocular muscle surgery for Graves' ophthalmopathy: does prior treatment influence surgical outcome?. Br J Ophthalmol 74 8 (1990) 481-483
65. Mocan M.C., Ament C., and Azar N.F. The characteristics and surgical outcomes of medial rectus recessions in Graves' ophthalmopathy. J Pediatr Ophthalmol Strabismus 44 2 (2007) 93-100
66. Coats D., Paysee E., Plager D., et al. Early strabismus surgery for thyroid ophthalmopathy. Ophthalmology 106 2 (1999) 324-329
67. Yolar M., Oguz V., Pazarli H., et al. Early surgery for dysthyroid orbitomyopathy based on magnetic resonance imaging findings. J Pediatr Ophthalmol Strabismus 39 6 (2002) 336-339
68. Kushner B. A surgical procedure to minimize lower-eyelid retraction with inferior rectus recession. Arch Ophthalmol 110 7 (1992) 1011-1014
69. Pacheco M., Guyton D., and Repka M. Changes in eyelid position accompanying vertical rectus muscle surgery and prevention of lower lid retraction with adjustable suture. J Pediatr Ophthalmol Strabismus 29 5 (1992) 265-272
70. Liao S., Shih M., and Lin A. A procedure to minimize lower lid retraction during large inferior rectus recession in Graves ophthalmopathy. Am J Ophthalmol 141 3 (2006) 340-345
71. Neoh C., and Eckstein A. Eyelid surgery. In: Wiersinga W.M., and Kahaly G.J. (Eds). Graves' orbitopathy: a multidisciplinary approach (2007), S Karger AG, Basel (Switzerland) 188-200
72. Velasco e Cruz A.A., and Vagner de Oliveira M. The effect of Müllerectomy on Kocher sign. Ophthal Plast Reconstr Surg 17 5 (2001) 309-315
73. Harvey J.T., Corin S., Nixon D., et al. Modified levator aponeurosis recession for upper eyelid retraction in Graves' disease. Ophthalmic Surg 22 6 (1991) 313-317
74. Mourits M.P., and Sasim I.V. A single technique to correct various degrees of upper lid retraction in patients with Graves' orbitopathy. Br J Ophthalmol 83 1 (1999) 81-84
75. Mourits M.P., and Koornneef L. Lid lengthening by sclera interposition for eyelid retraction in Graves' ophthalmopathy. Br J Ophthalmol 75 6 (1991) 344-347
76. Elner V.M., Hassan A.S., and Frueh B.R. Graded full-thickness anterior blepharotomy for upper eyelid retraction. Arch Ophthalmol 122 1 (2004) 55-60
77. Hintschich C., and Haritoglou C. Full thickness eyelid transsection (blepharotomy) for upper eyelid lengthening in lid retraction associated with Graves' disease. Br J Ophthalmol 89 4 (2005) 413-416
78. Terwee C.B., Dekker F.W., Mourits M.P., et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf) 54 3 (2001) 391-398
79. Perros P., Baldeschi L., Boboridis K., et al. A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur J Endocrinol 155 2 (2006) 207-211